Tin tức & Cập nhật

Treatment with dupilumab results in significant improvements in the signs and symptoms of moderate-to-severe atopic dermatitis (AD) in adult Asian patients without any serious adverse effects, a Singapore study has shown.

Adding cabozantinib to nivolumab and ipilimumab as first-line therapy, compared with placebo, results in prolonged progression-free survival (PFS) among untreated patients with advanced renal cell carcinoma (RCC), with no new safety signals seen, as shown by the results of the phase III COSMIC-313 study.